Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

80%

4 of 5 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 2

4(57.1%)

Phase 1

2(28.6%)

Phase 3

1(14.3%)

7Total

Phase 2(4)

Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT03500159Phase 2Terminated

Efficacy and Safety of AQX-1125 in Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Role: lead

NCT02324972Phase 2Completed

Pilot Efficacy and Safety Study of AQX-1125 in Atopic Dermatitis

Role: lead

NCT03478020Phase 1Completed

Oral AQX-1125 and Combination Oral Contraceptive Drug-Drug Interaction Study

Role: lead

NCT02858453Phase 3Unknown

Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome

Role: lead

NCT01882543Phase 2Completed

Efficacy and Safety of AQX-1125 in IC/BPS

Role: lead

NCT03185195Phase 1Completed

Phase 1 Absorption Distribution Metabolism and Excretion of AQX-1125

Role: lead

NCT01954628Phase 2Completed

Efficacy and Safety of AQX-1125 in Unstable COPD

Role: lead

All 7 trials loaded